Stock Events

Stock Events

Swedish Orphan Biovitrum AB 

€38.92
15
+€1.3+3.46% Thursday 07:45

Statistics

Day High
38.92
Day Low
38.92
52W High
39.08
52W Low
23.62
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
283.08
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16JulExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-8.3
-3.77
0.75
5.28
Expected EPS
2.97887142332
Actual EPS
N/A

Financials

14.93%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
4.54BRevenue
677.81MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow B6E.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.45B
Vertex Pharmaceuticals is a competitor because it also focuses on rare diseases, similar to Swedish Orphan Biovitrum, with a strong emphasis on cystic fibrosis treatments.
Biogen
BIIB
Mkt Cap27.06B
Biogen competes in the rare disease space, particularly in areas like spinal muscular atrophy and multiple sclerosis, overlapping with some of Swedish Orphan Biovitrum's therapeutic areas.
Gilead Sciences
GILD
Mkt Cap161.85B
Gilead Sciences competes with Swedish Orphan Biovitrum through its focus on antiviral drugs for HIV, hepatitis B, and hepatitis C, as well as its expansion into other areas of high unmet medical need.
AMGEN
AMGN
Mkt Cap185.74B
Amgen competes in the biopharmaceutical field, focusing on treatments for serious illnesses, including areas that overlap with Swedish Orphan Biovitrum's focus on rare diseases.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.46B
Regeneron Pharmaceuticals is a competitor due to its focus on developing and commercializing treatments for eye diseases, rare diseases, and cancer, areas that Swedish Orphan Biovitrum also targets.
Novo Nordisk
NVO
Mkt Cap182.6B
Novo Nordisk is a leading company in diabetes care but also competes in the biopharmaceutical space, including treatments for rare blood disorders, overlapping with Swedish Orphan Biovitrum's market.
Pfizer
PFE
Mkt Cap153.59B
Pfizer is a broad-based competitor, with a significant presence in rare diseases through its Rare Disease unit, making it a competitor across several of Swedish Orphan Biovitrum's therapeutic areas.
Astrazeneca
AZN
Mkt Cap294.17B
AstraZeneca, especially after its acquisition of Alexion Pharmaceuticals, competes in the rare disease market, directly challenging Swedish Orphan Biovitrum's portfolio of rare disease therapies.

About

There is no Profile data available for B6E.SG.
Show more...
CEO
Dr. Guido Oelkers Ph.D.
Employees
1862
Country
Sweden
ISIN
SE0000872095
WKN
000A0LA5K

Listings

MI
IT
1SOBI.MI
MU
DE
B6E.MU
STU
DE
B6E.STU
ST
SE
SOBI.ST

0 Comments

Share your thoughts

FAQ

What is Swedish Orphan Biovitrum AB stock price today?▼
The current price of B6E.F is €38.92 EUR — it has increased by +3.46% in the past 24 hours. Watch Swedish Orphan Biovitrum AB stock price performance more closely on the chart.
What is Swedish Orphan Biovitrum AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Swedish Orphan Biovitrum AB stocks are traded under the ticker B6E.F.
Is Swedish Orphan Biovitrum AB stock price growing?▼
B6E.F stock has risen by +6.51% compared to the previous week, the month change is a +5.36% rise, over the last year Swedish Orphan Biovitrum AB has showed a +47.2% increase.
When is the next Swedish Orphan Biovitrum AB earnings date?▼
Swedish Orphan Biovitrum AB is going to release the next earnings report on July 16, 2026.
What were Swedish Orphan Biovitrum AB earnings last quarter?▼
B6E.F earnings for the last quarter are 0.34 EUR per share, whereas the estimation was 0.33 EUR resulting in a +4.89% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Swedish Orphan Biovitrum AB revenue for the last year?▼
Swedish Orphan Biovitrum AB revenue for the last year amounts to 4.54B EUR.
What is Swedish Orphan Biovitrum AB net income for the last year?▼
B6E.F net income for the last year is 677.81M EUR.
How many employees does Swedish Orphan Biovitrum AB have?▼
As of May 01, 2026, the company has 1,862 employees.
In which sector is Swedish Orphan Biovitrum AB located?▼
Swedish Orphan Biovitrum AB operates in the Health & Wellness sector.
When did Swedish Orphan Biovitrum AB complete a stock split?▼
Swedish Orphan Biovitrum AB has not had any recent stock splits.
Where is Swedish Orphan Biovitrum AB headquartered?▼
Swedish Orphan Biovitrum AB is headquartered in Stockholm, Sweden.